Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4685 in Relapsed or Refractory T Cell Lymphoma
NCT05079282Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-4685 in T-cell lymphoma, sponsored by Ono Pharmaceutical. Primary endpoints: Treatment-Emergent Adverse Events at 1 year and Maximum Tolerated Dose at 3 weeks. Started Dec 2021; status: active, not recruiting.
02
Drugs
ONO-4685
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT05079282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079282.